

**MYM NUTRACEUTICALS INC.**

**CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**

**(Expressed in Canadian Dollars)**

**(Unaudited)**

**NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL  
STATEMENTS**

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the consolidated interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of the consolidated interim financial statements by an entity's auditor.

**MYM NUTRACEUTICALS INC.**  
**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
(Expressed in Canadian Dollars)  
(Unaudited)

	NOVEMBER 30 2017	MAY 31 2017
<b>ASSETS</b>		
<b>Current Assets</b>		
Cash	\$ 2,041,701	\$ 548,514
Amounts receivable (Note 3)	415,582	40,517
Deposits and prepaid expenses	370,091	208,601
Due from related parties (Note 14)	41,416	-
Notes receivable (Note 4)	129,950	-
Inventory (Note 5)	62,216	37,906
<b>Total Current Assets</b>	<b>3,060,956</b>	<b>835,538</b>
<b>Non-current Assets</b>		
Goodwill (Note 10)	888,056	888,056
Intangible assets (Note 7)	741,462	8,991
Property, plant, and equipment (Note 6)	1,930,568	35,781
<b>TOTAL ASSETS</b>	<b>\$ 6,621,042</b>	<b>\$ 1,768,366</b>
<b>LIABILITIES</b>		
<b>Current Liabilities</b>		
Accounts payable and accrued liabilities	\$ 328,278	\$ 255,659
Due to related parties (Note 14)	42,571	1,004
<b>Total Current Liabilities</b>	<b>370,849</b>	<b>256,663</b>
Royalty provision on acquisition (Note 11)	195,000	-
<b>Total Liabilities</b>	<b>565,849</b>	<b>256,663</b>
<b>EQUITY</b>		
Share capital (Note 13)	9,740,996	3,051,623
Share subscriptions received	7,500	843,582
Reserves	720,353	199,096
Contingent consideration (Note 10)	115,000	345,000
Deficit	(4,345,867)	(2,879,966)
<b>Equity attributable to shareholders of the Company</b>	<b>6,237,982</b>	<b>1,559,335</b>
Non-controlling interest	(182,789)	(47,632)
<b>Total Equity</b>	<b>6,055,193</b>	<b>1,511,703</b>
<b>TOTAL LIABILITIES AND EQUITY</b>	<b>\$ 6,621,042</b>	<b>\$ 1,768,366</b>

**Nature of operations and going concern** (Note 1)  
**Commitments and contingencies** (Note 18)  
**Events after the reporting period** (Note 19)

These consolidated financial statements were approved and authorized for issue for the Board of Directors on January 29, 2018. They are signed on the Company's behalf by:

*"Erick Factor"*

Director

*"Rob Gietl"*

Director

The accompanying notes are an integral part of these consolidated financial statements.

**MYM NUTRACEUTICALS INC.**  
**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND**  
**COMPREHENSIVE LOSS**  
(Expressed in Canadian Dollars)  
(Unaudited)

	THREE MONTHS ENDED NOVEMBER 30		SIX MONTHS ENDED NOVEMBER 30	
	2017	2016	2017	2016
<b>Revenues</b>	\$ 398,081	\$ -	\$ 678,529	\$ -
<b>Cost of Sales</b>	(148,192)	-	(242,358)	-
<b>Gross Profit</b>	249,889	-	436,171	-
<b>General and administrative expenses</b>				
Advertising, marketing and promotions	\$ 315,930	\$ 1,455	\$ 433,176	\$ 2,235
Depreciation	846	-	911	-
Consulting fees	151,677	10,750	191,760	21,500
Corporate filing and listing fees	9,837	5,758	16,119	9,730
Foreign exchange	474	-	609	-
Insurance	10,883	-	10,883	-
Interest and bank charges	1,094	106	1,405	155
Interest on notes payable (Note 12)	-	2,618	-	5,264
Meals and entertainment	15,992	45	23,866	287
Office and miscellaneous	41,310	424	73,738	1,085
Professional fees	81,804	4,055	102,144	5,349
Rent	46,217	-	72,688	-
Research and development	-	-	485	-
Salaries and management fees (Note 14)	203,729	15,000	429,498	30,000
Shipping and brokerage fees	22,861	-	34,955	-
Stock based compensation (Note 13)	313,041	-	573,739	6,183
Training and education	(675)	-	14,900	-
Travel	29,110	441	52,804	2,316
Utilities	1,471	-	3,549	-
	1,245,601	40,652	2,037,229	84,104
<b>Net Loss from Operations</b>	(995,712)	(40,652)	(1,601,058)	(84,104)
<b>Writedown of deposit</b>	-	-	-	(15,000)
<b>Net Loss And Comprehensive Loss</b>	\$ (995,712)	\$ (40,652)	\$ (1,601,058)	\$ (99,104)
<b>Net loss attributable to:</b>				
MYM Nutraceuticals Inc.	(918,165)	(40,652)	\$ (1,465,901)	(99,104)
Non-controlling interest	(77,547)	-	(135,157)	-
	(995,712)	(40,652)	\$ (1,601,058)	(99,104)
<b>Basic And Diluted Loss Per Common Share</b>	\$ (0.011)	\$ (0.001)	\$ (0.019)	\$ (0.002)
<b>Weighted Average Number Of Common Shares Outstanding</b>	86,656,667	53,652,709	83,075,541	53,475,391

The accompanying notes are an integral part of these consolidated financial statements.

**MYM NUTRACEUTICALS INC.**  
**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Expressed in Canadian Dollars)

	SIX MONTHS ENDED	
	NOVEMBER 30	
	2017	2016
<b>Cash Flows Provided By (Used In):</b>		
<b>Operating Activities</b>		
Net loss for the period	\$ (1,601,058)	\$ (99,104)
Items not affecting cash		
Amortization and depreciation	911	-
Share-based payments	573,739	6,183
Net change in non-cash working capital items:		
Accounts receivable	(375,065)	(2,142)
Deposits and prepaids	(161,490)	1,015
Inventory	(24,310)	-
Accounts payable and accrued liabilities	72,619	(783)
Due from related parties	151	55,098
Interest payable	-	5,264
Notes receivable	(129,950)	-
	<b>(1,644,453)</b>	<b>(34,469)</b>
<b>Financing Activities</b>		
Proceeds from private placements	3,394,300	600
Proceeds from exercise of warrants	1,727,804	-
Proceeds from exercise of options	204,500	-
Share issue costs	(119,608)	-
	<b>5,206,996</b>	<b>600</b>
<b>Investing Activities</b>		
Acquisition of assets	(17,793)	-
Acquisition of intangible assets	(173,658)	-
Construction in progress	(1,877,905)	-
	<b>(2,069,356)</b>	<b>-</b>
<b>Net Increase (Decrease) In Cash</b>	<b>1,493,187</b>	<b>(33,869)</b>
<b>Cash, Beginning Of The Period</b>	<b>548,514</b>	<b>145,156</b>
<b>Cash, End Of The Period</b>	<b>\$ 2,041,701</b>	<b>\$ 111,287</b>

Supplemental cash flow information (Note 17)

The accompanying notes are an integral part of these consolidated financial statement

**MYM NUTRACEUTICALS INC.**  
**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIENCY)**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

	<u>SHARE CAPITAL</u>		SHARES TO BE ISSUED AND SUBSCRIPTIONS RECEIVED	RESERVE WARRANTS OPTIONS	FOR AND	CONTINGENT CONSIDERATION	DEFICIT	NON CONTROLLING INTEREST	TOTAL EQUITY
Balance, May 31, 2016	53,300,001	1,644,748	25,525		164,047	-	(2,033,281)	-	(198,961)
Shares issued	746,428	26,125	(26,125)		-	-	-	-	-
Share subscriptions received	-	-	600		-	-	-	-	600
Stock based compensation	-	-	-		6,183	-	-	-	6,183
Net loss for the period	-	-	-		-	-	(99,104)	-	(99,104)
Balance, November 30, 2016	54,046,429	\$ 1,670,873	\$ -	\$ -	170,230	\$ -	\$ (2,132,385)	\$ -	\$ (291,282)
Shares issued	8,100,000	405,000	-		-	-	-	-	405,000
Shares issued for exercise of warrants	1,035,000	51,750	-		-	-	-	-	51,750
Shares issued for business acquisition	2,500,000	575,000	-		-	-	-	-	575,000
Shares issued for purchase of assets	1,000,000	65,000	-		-	-	-	-	65,000
Shares issued as finders' fees	800,000	184,000	-		-	-	-	-	184,000
Share subscriptions received	-	-	843,582		-	-	-	-	843,582
Stock based compensation	500,000	100,000	-		28,866	-	-	-	128,866
Contingent consideration	-	-	-		-	345,000	-	-	345,000
Net loss for the period	-	-	-		-	-	(747,581)	(47,632)	(795,213)
Balance, May 31, 2017	67,981,429	\$ 3,051,623	\$ 843,582	\$ -	199,096	\$ 345,000	\$ (2,879,966)	\$ (47,632)	\$ 1,511,703
Shares and warrants issued on private placements	11,982,120	3,780,244	(836,082)		450,138	-	-	-	3,394,300
Shares issued for exercise of warrants	13,099,761	1,727,804	-		-	-	-	-	1,727,804
Shares issued for exercise of options	847,500	204,500	-		-	-	-	-	204,500
Shares issued for business acquisitions <sup>(1)</sup>	1,962,500	593,813	-		-	(230,000)	-	-	363,813
Share issue costs	-	(119,608)	-		-	-	-	-	(119,608)
Fair value options exercised	-	71,136	-		(71,136)	-	-	-	-
Fair value of warrants issued for services	-	-	-		27,612	-	-	-	27,612
Fair value of warrants exercised	-	87,484	-		(87,484)	-	-	-	-
Stock based compensation	875,000	344,000	-		202,127	-	-	-	546,127
Net loss for the period	-	-	-		-	-	(1,465,901)	(135,157)	(1,601,058)
Balance, Nov 30, 2017	96,748,310	9,740,996	\$ 7,500	\$ -	720,353	\$ 115,000	\$ (4,345,867)	\$ (182,789)	\$ 6,055,193

(1) A summary of Shares issued for business acquisitions

CannaCanada Inc. acquisition	437,500	\$	202,188
CannaCanada Inc. finder's fee	25,000		8,625
Mary Jane's Touch acquisition	500,000		153,000
Hempmed acquisition contingent shares	1,000,000		230,000
Shares issued for business acquisitions	1,962,500	\$	593,813

The accompanying notes are an integral part of these consolidated financial statements.

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**1. NATURE OF OPERATIONS AND GOING CONCERN**

MYM Nutraceuticals Inc. (the “Company” or “MYM”) was incorporated pursuant to the Business Corporations Act of British Columbia (“BCABC”) on July 11, 2014, under incorporation number BC1002050. The address of the Company’s corporate office and principal place of business is Suite 1500 409 Granville Street, Vancouver, British Columbia, Canada. The Company was a wholly owned subsidiary of Salient Corporate Services Inc. and was created for the purpose of giving effect to an Arrangement Agreement among MYM, Salient Corporate Services Inc. (“Salient”), and Adera Minerals Corp. (“Adera”). Adera was incorporated on February 18, 2011 under the Business Corporations Act of British Columbia. During the year ended May 31, 2017, Adera Minerals Corp. was renamed to Joshua Tree Brands Inc.

The Company is in the business of acquiring and developing natural remedies and currently holds the rights to various intangible assets including intellectual property, domain names and copyrights, customer lists, and has two active applications to become a licensed producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) in Quebec, Canada.

Although the Company continues to invest resources for a medical marijuana business, there is no guarantee the Company will be awarded a license to grow medical marijuana nor is there a time frame available as to when the Company will be notified of the success of its application.

As at November 30, 2017, the Company has an accumulated deficit of \$4,345,867 (May 31, 2017 - \$2,879,966). The Company’s operations are mainly funded with equity financing, which is dependent upon many external factors and may be difficult to raise when required. The Company may not have sufficient cash to fund the acquisition and development to commercial production and therefore will require additional funding, which if not raised, may result in the delay, postponement or curtailment of some of its activities. Management continues to evaluate the need for additional financing and is of the opinion that additional financing will be available to continue its planned activities in the normal course. Nonetheless, there is no assurance that the Company will be able to raise sufficient funds in the future to complete its planned activities. All of which indicate the existence of a material uncertainty that may cast substantial doubt on whether the Company would continue as a going concern and realize its assets and settle its liability and commitments in the normal course of business.

The Company’s condensed interim consolidated financial statements (“interim financial statements”) have been prepared on the basis of accounting principles applicable to a going concern, which assume the realization of assets and discharge of liabilities in the normal course of business. These interim financial statements do not give effect to any adjustments that would be necessary should the Company not be able to continue as a going concern. Such adjustments could be material.

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**2. BASIS OF PRESENTATION**

a) Statement of Compliance

These interim financial statements, including comparatives, have been prepared in accordance with International Accounting Standard ("IAS") 34, *Interim Financial Reporting* using accounting policies consistent with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). Accordingly, these interim financial statements do not include all of the information and footnotes required by IFRS for complete financial statements for year-end reporting process.

b) Basis of Measurement

These interim financial statements have been prepared on a historical cost basis except for certain financial instruments that have been measured at fair value. In addition, these interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

c) Functional and Presentation Currency

The presentation and the functional currency of the Company and its subsidiaries is the Canadian dollar.

Transactions in currencies other than the functional currency are recorded at the rates of exchange prevailing on the dates of the transactions. At each financial position reporting date, monetary assets and liabilities that are denominated in foreign currencies are translated at the rates prevailing at the date of the statement of financial position. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

d) Significant Accounting Judgments and Estimates

The preparation of these interim financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. The interim financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and may affect both the period of revision and future periods.

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**2. BASIS OF PRESENTATION (continued)**

d) Significant Accounting Judgments and Estimates (continued)

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

Judgements:

- The carrying value and recoverable amount of intangible assets;
- the assumption that the Company is a going concern and will continue in operation for the foreseeable future and at least one year.
- The Company assesses the collectability of receivables on an ongoing basis. A provision for the impairment of receivables involves significant management judgment and includes the review of individual receivables based on individual customer creditworthiness, current economic trends and analysis of historical bad debts.
- The Company assesses whether the acquisitions should be accounted and disclosed as an acquisition of assets or acquisition of a business and involves significant judgement by management of the Company.

Estimates:

- The estimated useful lives of equipment which is included in the statements of financial position and the related depreciation included in net income/loss for the period;
- the inputs used in accounting for warrants issued;
- the inputs used in accounting for share-based compensation expense in net income/loss;
- the inputs used in accounting for acquisitions acquired thru shares and options issued;
- the inputs used in assessing the recoverability of deferred income tax assets to the extent that the deductible temporary differences will reverse in the foreseeable future and that the Company will have future taxable income.

e) Operating Segments

The Company currently operates in one operating segment, therefore the operating segments of the Company are treated as one reporting segment

f) Basis of Consolidation

These interim financial statements include the accounts of the Company and all of its subsidiaries: CannaCanada Inc., Joshua Tree Brands Inc., My Marijuana Natural Resources Inc., MYM Holdings Inc., MYM Holdings (WA) Inc. (incorporated in the State of Washington), Sublime Culture Inc., and 1114865 B.C. Ltd.

All subsidiaries are entities that we control, either directly or indirectly. Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when our existing rights give us the ability to direct the activities that significantly affect the investee's returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a company's share capital.



**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**2. BASIS OF PRESENTATION (continued)**

f) Basis of Consolidation (continued)

All of our intra-group balances and transactions, including unrealized profits and losses arising from intra-group transactions, have been eliminated in full. For subsidiaries that we control but do not own 100% of, the net assets and net profit attributable to outside shareholders are presented as amounts attributable to non-controlling interests in the consolidated statements of financial position and consolidated statements of operations and comprehensive loss.

**3. AMOUNTS RECEIVABLE**

	November 30, 2017	May 31, 2017
Trade receivables	\$ 54,338	\$ 10,038
GST/HST/QST receivables	318,241	27,466
Other receivables	46,940	6,950
Allowance for doubtful accounts	(3,937)	(3,937)
	<b>\$ 415,582</b>	<b>\$ 40,517</b>

An allowance for doubtful accounts of \$3,937 (May 31, 2017: \$3,937) has been provided against these receivable amounts, which the Company has determined represents a reasonable estimate of amounts that may be uncollectible. The other receivables are due from a company that processes our CBD products and sells them on behalf of the Company.

**4. NOTES RECEIVABLE**

On October 18, 2017, MYM announced a partnership with PUF Ventures Inc. (PUF) for the construction of a one million square foot facility called the Northern Rivers Project in New South Wales, Australia. The North Rivers Project is a partnership with the local government in New South Wales, Australia. MYM will own 35% of the Project, which will have the ability to produce at capacity 100,000 kilograms of cannabis, with an estimated top-line revenue between \$800 million and \$1.1 billion.

PUF has entered into an agreement in principal whereby it will receive a 70% interest comprising 70 shares in Solaris Nutraceuticals Pty Ltd. (formerly "PUF Ventures Australia") if certain funding obligations totalling USD\$1 million are made (the "Obligations"). PUF and MYM have entered into a Share Purchase Agreement whereby MYM will fund half of the Obligations, totalling USD\$500,000 in exchange for half of the shares (a 35% interest).

During the six months ended November 30, 2017, the Company loaned USD\$100,000 (CAD\$129,950) to PUF Ventures Inc. Once the share purchase agreement is completed and final agreements are signed, the balance will be applied to the following obligations:

The Company is obligated under the agreement to fund 50 percent of the following milestones

- |   |                                       |
|---|---------------------------------------|
| <p>1. Formation and Incorporation of Company</p> <ul style="list-style-type: none"> <li>-Setup of Australian Bank Accounts with foreign clients</li> <li>-Registration of Australian Business Number (ABN)</li> <li>-Business Systems implementation (domain, email/office, finance)</li> <li>-Engage Lawyers, Accountants</li> </ul> | <p><b>Investment \$50,000 USD</b></p> |
|---|---------------------------------------|

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**4. NOTES RECEIVABLE (Continued)**

2. Agreement with Council/Municipality on land **Investment \$150,000 USD**  
- Site Identification, Ballina, Byron Bay, Tweed Heads, Casino  
- Submission of RJIP Grant (submitted early to get on Government radar)  
- complete Site Negotiations, Ballina, Casino  
- Engage Greenhouse expert
3. Filing of applications to the Office of Drug Control for Cultivation **Investment \$250,000 USD**
4. Awarding of license from ODC **Investment \$550,000 USD**

**5. INVENTORY**

	<b>November 30, 2017</b>	May 31, 2017
Raw materials and packaging	\$ 11,375	\$ 9,000
Work in progress	6,631	-
Finished product	40,544	28,906
Marketing materials	3,666	-
	<b>\$ 62,216</b>	<b>\$ 37,906</b>

The costs of inventories recognized as an expense for the six months ended November 30, 2017, were \$242,358 (2016 - \$nil) and are included in cost of sales.

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**6. PROPERTY, PLANT, AND EQUIPMENT**

	Computers	Equipment	Construction in Progress	Total
<b>Cost</b>	\$	\$	\$	\$
Balance at May 31, 2016	-	-	-	-
Additions	900	-	34,915	35,815
<b>Balance at May 31, 2017</b>	<b>900</b>	<b>-</b>	<b>34,915</b>	<b>35,815</b>
Additions	1,156	16,637	1,877,905	1,895,698
<b>Balance at November 30, 2017</b>	<b>2,056</b>	<b>16,637</b>	<b>1,912,820</b>	<b>1,931,513</b>
<b>Accumulated depreciation</b>				
Balance at May 31, 2016	-	-	-	-
Depreciation for the year	34	-	-	34
<b>Balance at May 31, 2017</b>	<b>34</b>	<b>-</b>	<b>-</b>	<b>34</b>
Depreciation for the year	239	672	-	911
<b>Balance at November 30, 2017</b>	<b>273</b>	<b>672</b>	<b>-</b>	<b>945</b>
<b>Net carrying amounts</b>				
As at May 31, 2017	866	-	34,915	35,781
<b>As at November 30, 2017</b>	<b>1,783</b>	<b>15,965</b>	<b>1,912,820</b>	<b>1,930,568</b>

**7. INTANGIBLE ASSETS**

	ACMPR License Application	Intellectual Property	Domain Names	Other	Total
<b>Cost</b>	\$	\$	\$	\$	\$
Balance at May 31, 2016	-	-	3,350	1,500	4,850
Acquisitions	-	-	5,080	561	5,641
Impairment	-	-	-	(1,500)	(1,500)
<b>Balance at May 31, 2017</b>	<b>-</b>	<b>-</b>	<b>8,430</b>	<b>561</b>	<b>8,991</b>
Acquisitions	382,574	348,000	-	1,897	732,471
<b>Balance at November 30, 2017</b>	<b>382,574</b>	<b>348,000</b>	<b>8,430</b>	<b>2,458</b>	<b>741,462</b>

For the six months ended November 30, 2017, there are no indicators of impairment to intangible assets. During the year ended May 31, 2017, the Company recognized an impairment loss on documentation of \$1,500.

During the six months ended November 30, 2017, the Company entered into an asset purchase agreement to secure the exclusive rights to apply for an ACMPR license application with the City of Weedon (Note 8). The costs incurred to complete the licence application and the costs of obtaining the exclusive rights have been capitalized as an intangible asset. The Company also capitalized certain costs for the Laval ACMPR licence application: \$343,476 attributed to CannaCanada ACMPR; \$39,098 attributed to Sublime ACMPR (Note 9.)

Intellectual property of \$348,000 is the value of the assets acquired from MaryJanes Touch (Note 11).

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**8. ASSET ACQUISITION - CANNACANADA**

On June 8, 2017 (the "Closing Date") the Company acquired 75% of the outstanding common shares of CannaCanada Inc. ("CannaCanada"), a Montréal, Quebec based cannabis company. The initial consideration exchanged by the Company was cash consideration of \$105,000 cash and 187,500 common shares of the Company upon the closing of the agreement and further 250,000 shares subsequent to the Closing Date.

The Company will exchange the following additional consideration should the related milestones be achieved to trigger the issuance:

1. If the ACMPR License Application reaches the pre-license inspection stage, MYM will issue 500,000 common shares of MYM to CannaCanada.
2. If the ACMPR License Application is approved by Health Canada and the License is granted, MYM will issue 1,000,000 common shares of MYM to CannaCanada. When enacted MYM's ownership share will increase from 75% to 85%.
3. One year following the receipt of the license, MYM will issue 1,000,000 common shares of MYM to CannaCanada. When enacted MYM's ownership share will increase from 85% to 90%.
4. Once the Interpretation Centre is completed and operational, MYM will issue 1,000,000 common shares of MYM to CannaCanada.
5. Once the Hemp Facility is completed and operational, MYM will issue 1,000,000 common shares of MYM to CannaCanada.

Through the acquisition of CannaCanada, the Company entered into an exclusive deal with the Municipality of Weedon, Quebec, Canada to build a 1.5 million-square-foot cannabis facility consisting of fifteen 100,000-square-foot greenhouses. The acquisition has been accounted for by the Company as a purchase of assets and assumption of liabilities. The acquisition did not qualify as a business combination under *IFRS 3 - Business Combinations*, as the significant inputs, processes and outputs, that together constitute a business, do not currently exist in CannaCanada. The primary asset of CannaCanada is the value of the ACMPR License Application with the Municipality of Weedon and Health Canada.

Due to an administrative delay in issuing the initial shares, the Company amended the timing of the issuance of the 187,500 shares to June 20, 2017. The fair value of these shares was determined using MYM's closing share price from June 19, 2017 of \$0.345 for a total of \$64,688.

The total consideration was allocated to the assets acquired and liabilities based on their relative fair values on the Closing Date as follows:

<b>Purchase price</b>		
Cash consideration	\$	<b>105,000</b>
Fair value of common shares issued, net of share issuance costs of \$nil		<b>64,688</b>
Transactions costs		-
	<b>\$</b>	<b>169,688</b>
<b>Purchase price allocation</b>		
ACMPR license application	<b>\$</b>	<b>169,688</b>

The 250,000 subsequent shares were valued at \$0.55 per share for a total of \$137,500 on issue date and capitalized in the ACMPR license application costs.

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**9. ASSET ACQUISITION - SUBLIME**

On February 22, 2017, the Company acquired 51% interest in Sublime Culture Inc. (“Sublime”) and its inspection-stage application in Quebec to become a licensed producer of medical cannabis pursuant to the investment agreement dated January 27, 2017. The Company issued 1,000,000 common shares at a price of \$0.065 per share for a value of \$65,000. The Company is required to raise between \$1,800,000 and \$2,500,000 to fund the completion and operation of the facility and upon production start-up the Company will issue Sublime 200,000 options per year.

The acquisition has been accounted for by the Company as a purchase of assets and assumption of liabilities. The acquisition did not qualify as a business combination under *IFRS 3 - Business Combinations*, as the significant inputs, processes and outputs, that together constitute a business, do not currently exist in Sublime.

**10. BUSINESS ACQUISITION - HEMPMED**

On April 11, 2017, the Company acquired 100% of the brand and assets of HempMed (“HempMed”), a Toronto-based developer and marketer of hemp-based CBD extracts and oil-infused nutraceutical products. Pursuant to the Acquisition Agreement between MYM and HempMed, the Company issued 2,500,000 common shares of the Company to the owner of HempMed, with a further 1,500,000 common shares to be issued upon reaching certain monthly and annual sales targets.

The acquisition of “HempMed” by the Company is considered to be business combination. Pursuant to the business combination transactions, the asset acquired from the acquisition is to be recorded at their estimated fair values in accordance with *IFRS 3 – Business Combination*. The allocation of the purchase consideration is as follows:

<b>Purchase consideration</b>	
Fair value of shares	\$ 575,000
Fair value of contingent consideration	<u>345,000</u>
<b>Total purchase price</b>	<b>\$ 920,000</b>
<b>Allocation of purchase price:</b>	
Inventory	31,944
Goodwill	<u>888,056</u>
	 <u>\$ 920,000</u>

The fair value of the Company’s net assets is estimated to be consistent with their carrying value. The goodwill recognized in connection with the acquisition is primarily attributable to the application of the Company’s best practices to improve the operations of the companies acquired.

The estimated fair value of the contingent consideration liability recognized on the acquisition date is calculated using the fair value of the shares of the expected contingent consideration to be paid. During the six months ended November 30, 2017, the Company issued 1,000,000 of the contingent common shares as operational milestones were achieved by HempMed. Accordingly, \$230,000 representing the fair value of the issued shares was reclassified to share capital from the contingent consideration equity component.

<b>Reconciliation of Contingent Consideration</b>	
Balance, May 31, 2017	\$ 345,000
Value attributable to contingent shares issued	<u>(230,000)</u>
<b>Balance, November 30, 2017</b>	<b>\$ 115,000</b>

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**11. ASSET ACQUISITION – MARY JANES TOUCH**

On September 6, 2017, the Company announced that it has entered into an Asset Purchase and Consulting Agreement with 9609989 Canada Inc. (d.b.a. “Mary Jane’s Touch” or “MJT”), which manufactures and distributes cannabidiol (“CBD”) and CBD products derived primarily from hemp and possesses numerous formulations of CBD products and research on CBD and its principals. MJT has been supplying CBD to MYM’s subsidiary, Joshua Tree (“JT”), for use in Joshua Tree’s products. MYM wants to acquire MJT’s intellectual property and other assets to continue to develop its innovative nutraceutical products. The Company issued 500,000 common shares upon closing of this Agreement according to the following schedule and contractual restrictions: 125,000 shares will become free-trading six months after issuance, and 125,000 every six months thereafter. The CBD products are focused on the markets of AB, BC, and ON.

As the shares issued cannot be traded for an extended period, a value of \$249,848 was assigned to the 500,000 shares issued using the Black Scholes method (average volatility 68%, expected life 0.5-2 years, risk free rate 0.70-1.34%).

The Company also entered into a consulting agreement with the principals of MJT to provide consulting services for a term of five years with an option to extend for an additional five years to provide the following services: development of new methods of CBD extraction and new products; contracting and recruiting chemists, extract artists, bakers and other experts in the cannabis industry; design, construction, staffing and management of any new production facilities; obtaining a Natural Product Number (NPN).

As part of the consulting agreement. The Company issued 250,000 options to purchase shares at \$0.45 per share on September 5, 2017, to expire one year after each vesting date. The options will vest as follows:

- 25,000 to vest six months from the date of grant
- 25,000 to vest twelve months from the date of grant
- 25,000 to vest eighteen months from the date of grant
- 25,000 to vest twenty-four months from the date of grant
- 25,000 to vest thirty-two months from the date of grant
- 25,000 to vest thirty-six months from the date of grant
- 25,000 to vest forty-two months from the date of grant
- 25,000 to vest forty-eight months from the date of grant
- 25,000 to vest fifty-four months from the date of grant
- 25,000 to vest sixty months from the date of grant

The Company has also agreed to pay a commission of 1% on the first \$500,000 of gross sales of the Products and 0.5% thereafter produced in the production facilities. The net present value of the contingent liability for these royalty payments was valued at \$195,000 using a 6% discount rate and is recorded on the Statement of Financial Position.

**12. LOANS AND NOTES PAYABLE**

As at November 30, 2017 and May 31, 2017, the total loans due to related parties were \$nil as all prior loans were paid out in full.

The Company did not enter into any new loan agreements during the six months ended November 30, 2017. Interest expense for the six months ended November 30, 2017 was \$nil (2016: \$5,264)

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**13. SHARE CAPITAL**

a) Authorized

Unlimited common shares without par value.

Unlimited preferred shares (none issued).

b) Issued and Outstanding

During the six months ended November 30, 2017 the Company issued the following shares:

- The Company announced the closing of a non-brokered private placement of 5,502,120 units for gross proceeds of \$990,382 (\$0.18 per unit). Each unit is comprised of one common share and one non-transferable share purchase warrant with each warrant exercisable into one additional common share at a price of \$0.40 for a period of one year. The securities issued are subject to a four month and one day hold period under securities law. A finders' fee of \$720 was paid on the financing. A value of \$200,290 was assigned to the warrants issued using the Black Scholes method (average volatility 70%, expected life 0.75 years, risk free rate 0.70%).
- The Company announced the closing of a non-brokered private placement of 6,480,000 units for gross proceeds of \$3,240,000 (\$0.50 per unit). Each unit is comprised of one common share and one non-transferable share purchase warrant with each warrant exercisable into one additional common share at a price of \$0.40 for a period of one year. The securities issued are subject to a four month and one day hold period under securities law. Finders' fees of \$115,033 were paid on the financing. A value of \$249,848 was assigned to the warrants issued using the Black Scholes method (average volatility 69%, expected life 0.75 years, risk free rate 1.34%).
- The Company issued 13,099,761 shares for the exercise of warrants at \$0.05-\$0.40 per share for gross proceeds of \$1,727,804. The fair value of the warrants exercised \$87,484 was reclassified to share capital from reserves.
- The Company issued 847,500 shares for the exercise of options at \$0.05-\$0.48 per share for gross proceeds of \$204,500. The fair value of the options exercised \$71,136 was reclassified to share capital from reserves.
- The Company issued 187,500 shares at an issue price of \$0.345 and 250,000 shares at an issue price of \$0.55 to complete the initial acquisition of CannaCanada Inc. A finder's fee of 25,000 shares \$0.345 per share was issued on the transaction.
- Pursuant to the Acquisition Agreement between MYM and NetZero Group for the acquisition of the HempMed assets the Company issued 1,000,000 shares to the owner of NetZeroGroup upon reaching the required monthly sales target of \$75,000 per month over 3 consecutive months.
- The Company announced the appointment of a new Director who will serve as Executive Chairman. Pursuant to an executive agreement, the Company issued 500,000 common shares as a signing bonus. The Company recorded \$100,000 to stock-based compensation based on \$0.20 per share on date of issue.
- The Company issued 50,000 shares of the Company to a consultant as a signing bonus and agreed to issue an additional 100,000 shares if certain conditions for receipt and approval of a cultivation licence and approval for sales and distribution by health Canada. The Company recorded \$28,000 to stock-based compensation based on \$0.28 per share on date of issue.
- The Company issued 500,000 shares for the asset acquisition of MJT at a price of \$0.45 per share for a value of \$225,000.

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**13. SHARE CAPITAL (continued)**

- The Company issued 300,000 shares at an issue price of \$0.55 per share in satisfaction of a \$165,000 signing bonus for a consulting agreement with International Cannabis Consultants Co. (“**Incanco**”), leading authorities on the legal framework of cannabis legislation in Canada. The Company also agreed to pay three 50,000 share milestone bonuses on the 4, 8, and 12 month anniversary of the agreement. Incanco was also issued 150,000 common share purchase warrants (each a “Warrant”), with each Warrant entitling Incanco to acquire one common share in the capital of MYM for a period of 36 months from the Warrant’s grant date. The exercise price of each Warrant is \$0.55. A value of \$27,612 was assigned to the warrants issued using the Black Scholes method (average volatility 69%, expected life 1.5 years, risk free rate 1.34%).
- The Company issued 25,000 shares of the Company to a Quality Assurance consultant as a signing bonus at an issue price of \$2.04 for a value of \$51,000 charged to Stock based compensation.

During the year ended May 31, 2017 the Company issued the following shares:

- 746,428 units were issued at a price of \$0.035 per unit for gross proceeds of \$26,125. Each unit consists of one common share and one non-transferable share purchase warrant. Each warrant entitles the holder to acquire one additional common share exercisable until October 18, 2018 at a price of \$0.05 per warrant share. No finders’ fees are payable on this placement.
- 8,100,000 units were issued at a price of \$0.05 per unit for gross proceeds of \$405,000. Each unit consists of one common share and one non-transferable share purchase warrant. Each warrant entitles the holder to acquire one additional common share exercisable until February 9, 2019 at a price of \$0.07 per warrant share. No finders’ fees are payable on this placement.
- 1,035,000 shares were issued for the exercising of warrants at \$0.05 per share for gross proceeds of \$51,750.
- 1,000,000 shares were issued for the 51% acquisition of Sublime Culture Inc at a price of \$0.065 per share for a value of \$65,000.

b) Issued and Outstanding (continued)

- 2,500,000 shares were issued for the business acquisition of HempMed at a price of \$0.23 per share for a value of \$575,000.
- 800,000 shares were issued as a finder’s fees for the HempMed acquisition at a price of \$0.23 per share for a value of \$184,000.
- 500,000 shares were issued in lieu of a Cash signing bonus for the hiring of a new CEO \$0.20 per share for a value of \$100,000. The amount is included with stock-based compensation on the statement of operations and comprehensive loss.

c) Escrow Shares

There were no shares held in escrow as at November 30, 2017 or May 31, 2017.



**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**13. SHARE CAPITAL (continued)**

d) Warrants

A summary of the changes in the Company's share purchase warrants is as follows:

	Number of warrants	Weighted Average Exercise Price
Balance, May 31, 2016	4,445,000	\$ 0.07
Issued	8,846,428	\$ 0.07
Exercised	(1,035,000)	\$ 0.05
Expired	(15,000)	\$ (0.10)
<b>Balance, May 31, 2017</b>	<b>12,241,428</b>	<b>\$ 0.07</b>
Issued	12,132,120	\$ 0.72
Exercised	(13,099,761)	\$ 0.13
<b>Balance, November 30, 2017</b>	<b>11,273,787</b>	<b>\$ 0.70</b>

The share purchase warrants outstanding and exercisable at November 30, 2017 are:

Number of warrants	Exercise price	Expiry date
100,000	\$ 0.08	December 4, 2017
300,000	\$ 0.05	April 29, 2018
3,098,787	\$ 0.40	June 2, 2018
60,000	\$ 0.05	October 18, 2018
5,709,000	\$ 1.00	October 24, 2018
771,000	\$ 1.00	November 7, 2018
1,085,000	\$ 0.07	February 9, 2019
150,000	\$ 0.55	September 20, 2020
<b>11,273,787</b>		

e) Incentive Stock Options

The Company's Stock Option Plan ("the Plan") follows the policies of the TSX Venture Exchange regarding stock option awards granted to employees, directors and consultants. The stock option plan allows a maximum of 10% of the issued shares to be reserved for issuance under the plan.

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**13. SHARE CAPITAL (continued)**

e) Incentive Stock Options (continued)

The following grants were made during the six months ended November 30, 2017:

- 1,000,000 options at an exercise price of \$0.23 per share. The options shall vest 12.5% quarterly with the final amount to vest at 25% over the two-year term of the agreement. The fair value of the options at grant date was \$88,318, of which \$54,185 was recorded in the six months ended November 30, 2017 based on vesting periods.
- 500,000 options at an exercise price of \$0.48 per share. 300,000 options vest immediately and the balance will vest upon completing a financing of \$2,500,000. The fair value of the options at grant date was \$68,038, of which \$57,241 was recorded in the six months ended November 30, 2017 based on vesting periods.
- The Company issued 250,000 options to purchase shares at \$0.45 per share on September 5, 2017, to expire one year after each vesting date. The options will vest as follows:
  - 25,000 to vest six months from the date of grant
  - 25,000 to vest twelve months from the date of grant
  - 25,000 to vest eighteen months from the date of grant
  - 25,000 to vest twenty-four months from the date of grant
  - 25,000 to vest thirty-two months from the date of grant
  - 25,000 to vest thirty-six months from the date of grant
  - 25,000 to vest forty-two months from the date of grant
  - 25,000 to vest forty-eight months from the date of grant
  - 25,000 to vest fifty-four months from the date of grant
  - 25,000 to vest sixty months from the date of grant

The fair value of the options at grant date was \$44,744, of which \$4,986 was recorded in the six months ended November 30, 2017 based on vesting periods.

The following grants were made during the year ended May 31, 2017:

- 250,000 options to a director with an exercise price of \$0.20. The options vest 25% after each 3-month anniversary. As at May 31, 2017 the fair value of the options at grant date was \$24,462, of which \$11,201 was recorded in the six months ended November 30, 2017 and \$13,992 was recorded in prior year based on vesting periods.
- 2,000,000 options to the CEO with an exercise price of \$0.20. The options vest 12.5% after each three-month anniversary with the final 25% vesting after 21 months. The fair value of the options at grant date was \$146,636, of which \$75,308 was recorded in the six months ended November 30, 2017 and \$14,874 was recorded in prior year based on vesting periods.
- 100,000 options previously granted were extended a further six months to November 2017. No additional stock-based compensation was required in 2017 as a result of the modification of the award.

Assumptions used in the option-pricing model are as follows for the six months ended November 30:

	<b>2017</b>	<b>2016</b>
Risk-free interest rate	<b>0.70-1.34%</b>	0.72%
Expected life	<b>1-5 years</b>	2 years
Expected volatility	<b>68-70%</b>	70%
Forfeiture rate	<b>0.0%</b>	0.0%
Dividend rate	<b>0.0%</b>	0.0%

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**13. SHARE CAPITAL (continued)**

e) Incentive Stock Options (continued)

A summary of the changes in the Company's stock options is as follows:

	Number of Options	Weighted Average Exercise Price
Balance, May 31, 2016	3,600,000	\$0.05
Granted	2,250,000	\$0.20
<b>Balance, May 31, 2017</b>	<b>5,850,000</b>	<b>\$0.11</b>
Granted	1,750,000	\$0.33
Exercised	(847,500)	\$0.24
<b>Balance November 30, 2017</b>	<b>6,752,500</b>	<b>\$0.15</b>

The following table summarizes the Company's stock options outstanding and exercisable at November 30, 2017:

NUMBER OF OPTIONS OUTSTANDING	NUMBER OF OPTIONS EXERCISABLE	EXERCISE PRICE	EXPIRY DATE
-	100,000	0.10	November 13, 2017
90,000	140,000	0.05	February 17, 2018
62,500 *	-	0.20	February 8, 2019
2,000,000 **	500,000	0.20	April 28, 2019
3,150,000	3,150,000	0.05	November 17, 2020
1,000,000 **	125,000	0.23	June 1, 2019
200,000 ***	-	0.48	August 8, 2019
250,000 ****	-	0.45	August 8, 2019
<b>6,752,500</b>	<b>3,865,000</b>		

\* vested as follows: 25% after each 3-month anniversary.

\*\* vested as follows: 12.5% after each 3-month anniversary and 25% after 21 months.

\*\*\* balance of 200,000 options have contingent vesting on attaining a financing of \$2.5M.

\*\*\*\* various vesting dates as noted above

**14. RELATED PARTY BALANCES AND TRANSACTIONS**

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company's executive officers and Board of Director members.

The aggregate value of transactions relating to key management personnel were as follows:

	SIX MONTHS ENDED NOVEMBER 30	
	2017	2016
Salaries and benefits and management fees	\$ 267,470	\$ 49,500
Stock-based compensation (vested during the period)	132,656	6,183
Total salaries and other short-term benefits	<b>\$ 400,126</b>	<b>\$ 55,683</b>

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**15. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)**

As at November 30, 2017, \$42,571 (May 31, 2017 - \$1,004) were owing to key management personnel or to a company controlled by a director or key management personnel and the amounts were included in due to related parties. The amounts payable are non-interest bearing, are unsecured, and have no specific terms of repayment.

During the six months ended November 30, 2017, the Company advanced \$100,000 to a Company controlled by a director of a subsidiary. The funds advanced were used to pay expenditures incurred on behalf of the Company. As at November 30, 2017, there is no balance remaining in the advance account.

During the six months ended November 30, the Company advanced funds to directors in the amount of \$41,416 (May 31, 2017: Nil) for travel expenses and tax deductions for options exercised. The funds were reimbursed in full subsequent to the quarter end.

**15. MANAGEMENT OF CAPITAL**

The Company's objectives when managing capital are to pursue and complete the identification and evaluation of assets, properties or businesses with a view to acquisition. The Company does not have any externally imposed capital requirements to which it is subject.

As at November 30, 2017, the Company had capital resources consisting of cash. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares or adjust the amount of cash and cash equivalents.

The Company's investment policy is to invest excess cash in investment instruments at high credit quality financial institutions with terms to maturity selected with regards to the expected time of expenditures from continuing operations.

The Company's ability to continue as a going concern is dependent upon successful completion of additional financing, continuing support of creditors and its ability to attain profitable operations.

**16. FINANCIAL RISK EXPOSURE AND RISK MANAGEMENT**

The Company is exposed in varying degrees to a number of risks arising from financial instruments. Management's close involvement in the operations allows for the identification of risks and variances from expectations. The Company does not participate in the use of financial instruments to mitigate these risks and has no designated hedging transactions. The Board approves and monitors the risk management processes. The Board's main objectives for managing risks are to ensure liquidity, the fulfillment of obligations, the continuation of the Company's exploration activities, and limited exposure to credit and market risks. There were no changes to the objectives or the process from the prior period.

The types of risk exposure and the way in which such exposures are managed are as follows:

a) Credit Risk:

Credit risk primarily arises from the Company's cash and cash equivalents and amounts receivable. The risk exposure is limited to their carrying amounts at the statement of financial position date. Cash and cash equivalents are held as cash deposits or invested in guaranteed investment certificates with various maturity dates. The Company does not invest in asset-backed deposits or investments and does not expect any credit losses. The Company periodically assesses the quality of its investments and is satisfied with the credit rating of the bank and the investment grade of the guaranteed investment certificates. Amounts receivable primarily consists of Trade Receivables and Goods and Services Tax ("GST") credits.

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**16. FINANCIAL RISK EXPOSURE AND RISK MANAGEMENT (Continued)**

b) Liquidity Risk:

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company ensures there is sufficient capital to meet short term business requirements. One of management's goals is to maintain an optimal level of liquidity through the active management of assets, liabilities and cash flows.

The Company's cash and cash equivalents are deposited in major banks or invested in guaranteed investment certificates, which are available on demand to fund the Company's operating costs and other financial demands.

c) Market Risk:

The significant market risks to which the Company is exposed are currency and interest rate risk.

d) Currency Risk:

The operating results and financial position of the Company are reported in Canadian dollars. As the Company is exploring opportunities in an international environment, some of the Company's financial instruments and transactions are denominated in currencies other than the Canadian dollar. The results of the Company's operations are subject to currency risk.

The majority of the Company's costs are incurred in Canada and are denominated in Canadian dollars. Foreign currency transactions are booked at historical cost in Canadian dollars.

e) Interest Rate Risk:

The Company's policy is to invest excess cash in guaranteed investment certificates at fixed or floating rates of interest and cash equivalents are to be maintained in floating rates of interest in order to maintain liquidity, while achieving a satisfactory return for shareholders. As at November 30, 2017 and May 31, 2017 no cash was held in interest bearing deposits. Fluctuations in interest rates impact the value of cash and cash equivalents. The Company manages risk by monitoring changes in interest rates in comparison to prevailing market rates.

Currently, the Company believes that it is not exposed to significant interest, currency or credit risks arising from its financial instruments.

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**17. SUPPLEMENTAL CASH FLOW INFORMATION**

	<b>SIX MONTHS ENDED NOVEMBER 30</b>	
	<u>2017</u>	<u>2016</u>
<b>Non-Cash Financing And Investing Activities</b>	<b>\$</b>	<b>\$</b>
Fair value of options exercised	(71,136)	-
Fair value of warrants issued in private placements	450,138	-
Fair value of warrants issued for services	27,612	-
Fair value of warrants exercised	(87,484)	-
Shares issued for purchase CannaCanada Inc (Note 7)	202,188	-
Shares issues for HempMed contingent consideration	230,000	-
Shares issued for finder's fees on CannaCanada	8,625	-
Shares issued for acquisition of MJT Assets	225,000	-

**18. COMMITMENTS AND CONTINGENCIES**

The Company has entered into two long term lease agreements for properties to be used for Sublime Culture Inc. in Laval, Quebec.

Effective March 1, 2017 continuing to February 28, 2022, with options to extend for three additional five- year terms, the Company has committed to lease a commercial building with an area of approximately 10,000 sq. ft. The base rent is set at \$7,083 per month plus GST and QST and will be increased annually to an amount equal to the IPC Montreal region for the last year or a minimum of two percent. The base rent can be reset at each renewal period to reflect appraised market prices at that time.

Effective October 1, 2017 continuing to September 22, 2022, with options to extend for three additional five-year terms, the Company has committed to lease an additional commercial building adjacent to the first with an area of approximately 10,000 sq. ft. The base rent is set at \$7,083 per month plus GST and QST and will be increased annually by an amount equal to the IPC Montreal region for the last year or a minimum of two percent. The base rent can be reset at each renewal period to reflect appraised market prices at that time.

The minimum payments over the next five years are as follow:

2018	141,660
2019	169,992
2020	169,992
2021	169,992
2022	169,992
	\$ 821,628

During the six months ended November 30, 2017, the Company entered into a five-year lease agreement to house the manufacturing of the Company's CBD operations in Toronto. The lease is effective December 1, 2017.

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**18. COMMITMENTS AND CONTINGENCIES (Continued)**

The minimum payments over the next five years are as follow:

2018	123,505
2019	128,240
2020	132,975
2021	137,710
2022	130,213
	<hr/>
	\$ 652,641

The acquisition of CannaCanada comprises a number of contingent consideration items that may be realized upon the attainment of certain milestones. If fully realized the Company has committed to issue a further 4,500,000 common shares (Note 8). Additionally, within the purchase agreement, the Company has agreed to provide future funding for up to \$270,000 towards the ACMPR License Application. As of November 30, 2017, the Company had funded \$255,630 of the \$270,000.

With the acquisition of Sublime, the Company committed to raise between \$1,800,000 and \$2,500,000 to fund the completion and operation of the facility and upon production start-up the Company will issue Sublime 200,000 options per year (Note 9).

With the acquisition of HempMed, the Company has committed to issue a further 500,000 common shares as a contingent consideration item that may be realized upon the attainment of certain milestones (Note 10).

**19. EVENTS AFTER THE REPORTING PERIOD**

On December 6, the Company granted 300,000 stock options to a new director. The options are exercisable for a period of 3 years at \$2.67 per share and will vest in equal proportions quarterly over the three years.

On December 7, 2017, the Company announced completion of a financing of 240,000 common shares at \$2.50 per share for gross proceeds of \$600,000.

On December 18, 2017, the Company issued 175,000 shares and granted 140,000 options to a consultant for a 3-year consulting term. The consultant shall provide MYM with consulting services focused on helping MYM and its partners obtain a license for and construct a medical marijuana production facility in Richmond Valley, Australia. In lieu of consulting fees, MYM granted 140,000 options to purchase common shares in the capital of MYM, with an exercise price of \$3.37. The options shall vest in accordance with the following schedule, and expire one year after vesting:

- (a) 14,000 on the 3-month anniversary of the Effective Date;
- (b) 14,000 on the 6-month anniversary of the Effective Date;
- (c) 14,000 on the 9-month anniversary of the Effective Date;
- (d) 14,000 on the 12-month anniversary of the Effective Date;
- (e) 14,000 on the 15-month anniversary of the Effective Date;
- (f) 14,000 on the 18-month anniversary of the Effective Date;
- (g) 14,000 on the 21-month anniversary of the Effective Date;
- (h) 14,000 on the 24-month anniversary of the Effective Date;
- (i) 14,000 on the 27-month anniversary of the Effective Date; and
- (j) 14,000 on the 30-month anniversary of the Effective Date.

**MYM NUTRACEUTICALS INC.**  
**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017**  
(Expressed in Canadian Dollars)  
(Unaudited)

**19. EVENTS AFTER THE REPORTING PERIOD (Continued)**

On December 29, 2017 the Company announced that certain officers and directors of the Company would be participating in an Automatic Share Disposition Plan (ASDP). The objective of the ASDP is to facilitate the sale of common shares of MYM currently held by insiders on the open market over a period of up to two years at prevailing market prices. The ASDP will allow those MYM insiders to sell their shares in order to further diversify their respective portfolios.

On December 29, 2017, the Company announced a non-brokered private placement of up to 3,571,000 units to be offered at a price of \$2.80 per unit for gross proceeds of \$10,000,000. Each unit consists of one common share and one transferable share purchase warrant. Each warrant entitles the holder to acquire one additional common share exercisable for 24 months at a price of \$4.00 per warrant share. Finders' fees up to 7.5% may be paid on this placement. The issuance of any shares or warrants are subject to approval of the regulatory authorities.

On January 8, 2018, the Company announced it has entered into a binding letter of intent with Budly Software Inc. ("Budly"), a leading software company that has developed a smartphone-enabled sales and distribution system connecting medicinal cannabis patients with local dispensary drivers for fast delivery and monitoring of orders. Using the system, a customer can select a dispensary, place an order, and then choose a driver to deliver it. The customer can then track the order on his smartphone and knows exactly when it will arrive. Orders can be placed via the Budly app on iOS, Android and Windows phones, and via the website [www.budly.com](http://www.budly.com). Pursuant to the letter of intent, MYM will issue 800,000 common shares to Budly in exchange for all non-U.S. rights to Budly's software and intellectual property. Should federal legislation change in the States, MYM will have first right of refusal for the rights in that country. The completion of the transaction is subject to the approval of the Canadian Securities Exchange.

On January 18, 2018 the Company entered into a consulting agreement with a Master Breeder at the Sublime facility in Laval, Québec. Pursuant to the five-year consulting agreement, the consultant will receive a signing bonus of \$25,000, paid in 7,062 MYM common shares at a deemed price per share of \$3.54.

On January 19, 2018, the Company issued 50,000 milestone shares to a consultant.

On January 22, 2018 the Company announced it has signed a Memorandum of Understanding (MOU) with NEWCANNA S.A.S., a leading Colombian medical cannabis company. MYM and NEWCANNA are proposing a joint venture or partnership agreement in which they would form a new, jointly owned company in Colombia. This partnership would focus on the large-scale commercial cultivation and transformation of cannabis and hemp for medical, scientific and industrial purposes and export to worldwide markets.

Subsequent to the period end, 1,211,380 warrants were exercised for proceeds of \$341,058.

Subsequent to the period end, 2,340,000 options were exercised for proceeds of \$117,000.